The cannabis industry could be worth $57B by 2027: Here’s how to invest

Over the past few years, the world has come to learn about cannabis and its medicinal qualities. The plant’s contribution to pain relief, cancer treatment and other medical issues has been researched and documented, and a booming industry has started to grow around it. The cannabis industry is growing rapidly, and according to recent predictions, it is expected to reach $57 billion worldwide by 2027¹.

Invest in Cannabis Stocks
Your Capital is at risk.

The status of medicinal marijuana has changed drastically over the last decade. Cannabis is gaining wider acceptance globally for its medicinal qualities, with increasing numbers of countries legalising its medicinal use. In addition, clinical research on medicinal marijuana is continuously increasing, some of it conducted by major pharmaceutical companies.

The medical cannabis industry

Cannabis is picking up substantial attention from investors. In 2019, the legal cannabis industry in the US was estimated at $13.6 billion with 340,000 relevant jobs in different fields, such as cultivation, production and distribution2. The popularity of cannabis seems to be on the rise, and so is the interest of investors in medical marijuana companies.

Not all cannabis companies deal with simply growing and selling the product; some develop cannabis-based pharmaceuticals, while others support startups in the field. Many cannabis companies are also stepping up their research, trying to establish the effects cannabis may have on different health issues. Below are some of the interesting names in the cannabis industry.


Active in the wellness, beauty and clean health markets, Amyris (AMRS) is a synthetic biotechnology and renewable chemical company. Valued at $4.1 billion, Amyris is aiming to provide alternative and new ways to concentrate cannabinoids.

Invest in Amyris With 0% Commission
Your capital is at risk. Other fees apply. 

Aurora Cannabis Inc.

Based in Edmonton, Canada, Aurora Cannabis Inc. (ACB) is a licensed manufacturer of marijuana products, with a variety of medical and consumer brands. Boasting a market cap of $1.6 billion, the company implements technology across all its functions, from cultivation to customer care.

Invest in Aurora With 0% Commission
Your capital is at risk. Other fees apply. 

The Cronos Group

The Cronos Group (CRON) is another Canada-based global cannabinoid company focused on research, technology, production and distribution of cannabis-based health solutions.  Cronos ended the first quarter of 2021 with $1.2 billion in cash, and its market cap is valued at $2.8 billion.

Invest in Cronos With 0% Commission
Your capital is at risk. Other fees apply. 


Organigram (OGI) is a company producing medical cannabis. The company operates locally in Canada, and exports its products internationally. In 2020, Organigram reported revenue of $69.6 million and an 8% year-over-year growth3.

Invest in Organigram With 0% Commission
Your capital is at risk. Other fees apply. 


Founded in 2013, Tilray (TLRY) was the first licensed producer of medical marijuana to be certified in accordance with European Medicine Agency (EMA) standards. The $6.6 billion pharmaceutical and cannabis company operates globally in Australia, Canada, Europe and Latin America.

Invest in Tilray With 0% Commission
Your capital is at risk. Other fees apply. 

Investing in the cannabis industry

The cannabis industry has been attracting wider recognition in recent years,  with increasing interest coming from the health-care sector. With more research and new technology constantly being developed, investors are showing interest, and cannabis companies are leaving their mark on the market.

Invest in Cannabis Stocks

Zero commission means that no broker fee will be charged when opening or closing the position and does not apply to short or leveraged positions. Other fees apply. Your capital is at risk. For more information, visit

This is a marketing communication and should not be taken as investment advice, personal recommendation, or an offer of, or solicitation to, buy or sell any financial instruments. This material has been prepared without taking any particular recipient’s investment objectives or financial situation into account, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared utilising publicly available information.